Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).



Status:Active, not recruiting
Conditions:Prostate Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:4/3/2019
Start Date:March 18, 2019
End Date:August 30, 2019

Use our guide to learn which trials are right for you!

DescriPtive Analysis of Real-world Clinical Outcomes of Second Line (2L) Novel Anti-HormonE Therapy (NAH) or RadIum-223 (Xofigo) in Patients With Metastatic Castration Resistance Prostate Cancer (mCRPC) After First Line (1L) NAH Therapy

In this study researcher want to learn more about the overall survival in patients suffering
from prostate gland cancer which spread outside the prostate to other parts of the body who
received either a novel anti-hormone therapy (NAH) or Radium-223 (Xofigo) after a prior NAH
therapy (first line treatment). Additionally the researchers are also interested in the
occurrence of bone fractures and other skeletal events. Basis for this study will be the US
based Flatiron database which provides access to clinical data for cancer patients.


Inclusion Criteria:

- Patients with documented mCRPC receiving 1L NAHs.

- Initiation of Ra-223 after 1L NAH therapy, or

- Initiation of sequential NAH therapy after 1L NAH therapy

Exclusion criteria:

- Patients involved in clinical trials

- Patients who received combined therapies in 1L or 2L
We found this trial at
1
site
Whippany, New Jersey 07981
?
mi
from
Whippany, NJ
Click here to add this to my saved trials